Tanezumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (from mouse) |
| Target | NGF |
| Clinical data | |
| Legal status | ? |
| Identifiers | |
| CAS number | 880266-57-9  |
| ATC code | None |
| UNII | EQL0E9GCX1  |
| Synonyms | RN624 |
| Chemical data | |
| Formula | C6464H9942N1706O2026S46 |
| Mol. mass | 145.4 kDa |
| (what is this?) (verify) | |
Tanezumab (INN, codenamed RN624) is a monoclonal antibody against nerve growth factor. It was developed by Pfizer as a treatment for pain.[1]
In 2009 there was a Phase III trial for knee pain due to osteoarthritis (OA).[2] Another phase III trial for hip pain in OA [3] was halted in June 2010 when some patients needed hip replacement.[4]
Tanezumab is undergoing Phase II clinical trials for the treatment of various pain entities, including chronic low back pain, bone cancer pain, and interstitial cystitis.[5]
In march of 2012 the Anti-NGF Testing - FDA Committee voted in favor of a continuation of the development of nerve-blocking medications, as long as certain safety precautions were observed.
References
http://www.medicalnewstoday.com/articles/242848.php
External links
| |||||||||||||||||||||||||||||||||||||||||||||